跳至主要内容
临床试验/RBR-2qcjbf
RBR-2qcjbf招募中未知

Clinical and biological outcomes of tramadol pharmacological adjunct therapy for Major Depressive Disorder - OpidoIDSS Opioids Inflamation Depression Stresse Suicide

Hospital das Clínicas de Ribeirão Preto0 个研究点开始时间: 2019年6月6日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
0 至 0(—)

入选标准

  • Clinical diagnosis of Severe depressive episode without psychotic symptoms and score 17 or over of Hamilton Depression Rating Scale (HAM-D)

排除标准

  • Diagnoses of bipolar affective disorder or previous manic episode; obsessive-compulsive disorder; eating disorder; patients with clinical use of antipsychotics; psychoactive substance use disorder; pregnant and lactating women; carriers of liver diseases; renal volume carriers (clearance <30); who are using medications with potential interaction with tramadol or with another serious medical illness: with comorbidities that affect the immune system, including autoimmune or comorbid disease (eg: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, etc.); recent consultation requiring antibiotics in the last month; chronic infections (human immunodeficiency virus, Hepatitis B and C); historic of cancer current or prehistoric, that are in use of medical communications in system of anti-inflammatory inflammatory (ex: glucocorticoids, non-steroidal anti-inflammatory agents). Also excluded from the study are patients who use antidepressants, antipsychotics or mood stabilizers.

研究者

发起方
Hospital das Clínicas de Ribeirão Preto

相似试验